300841.SHE Chengdu Kanghua Biological Products
- Market cap
- CNY 6.50B
- P/E
- 24.7x
- P/B
- 1.68x
- ROE
- 8.2%
- Dividend yield
- 2.10%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300841.SHE undervalued?
Graham number300841.SHE trades 35.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chengdu Kanghua Biological Products fundamental analysis
No fundamental analysis for Chengdu Kanghua Biological Products yet.
Chengdu Kanghua Biological Products stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, and operation of biological products in China. It offers freeze-dried human rabies vaccines; ACYW135 meningococcal polysaccharide vaccine. The company was founded in 2004 and is based in Chengdu, China.
Full company profileChengdu Kanghua Biological Products financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chengdu Kanghua Biological Products annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 92.9M | 262M | 559M | 555M | 1.04B | 1.29B | 1.45B | 1.58B | 1.43B | 1.17B | 1.18B |
| Gross Profit | 76.3M | 233M | 523M | 520M | 976M | 1.21B | 1.34B | 1.47B | 1.35B | 1.07B | 1.05B |
| Operating Income | 6.73M | 90.9M | 190M | 223M | 485M | 916M | 686M | 577M | 467M | 273M | 330M |
| EBITDA | 26.4M | 105M | 198M | 229M | 478M | 629M | 643M | 652M | 595M | 340M | 332M |
| Net Income | 6.66M | 74.5M | 154M | 187M | 408M | 829M | 598M | 509M | 399M | 220M | 303M |
| EPS | 0.05 | 0.55 | 1.54 | 1.38 | 3.02 | 6.14 | 4.46 | 3.81 | 3.03 | 1.69 | 2.33 |
| Balance Sheet | |||||||||||
| Total Assets | 201M | 275M | 486M | 689M | 2.15B | 3.02B | 3.71B | 4.21B | 4.03B | 4.01B | 4.40B |
| Total Liabilities | 297M | 86.4M | 118M | 114M | 173M | 348M | 635M | 695M | 580M | 472M | 472M |
| Shareholders' Equity | -96.2M | 188M | 368M | 575M | 1.97B | 2.67B | 3.08B | 3.51B | 3.45B | 3.54B | 3.70B |
| Cash & Short-term Investments | 9.85M | 62.6M | 92.4M | 242M | 1.33B | 927M | 651M | 1.04B | 1.00B | 1.15B | 310M |
| Total Debt | 416K | 7.50M | 19.0M | 10.0M | 2.34M | 901K | 126M | 191M | 187M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.64M | 90.0M | 57.4M | 183M | 370M | 130M | 195M | 574M | 572M | 380M | - |
| Capital Expenditure | 1.86M | 4.53M | 34.6M | 24.0M | 136M | 315M | 419M | 157M | 144M | 70.8M | 39.4M |
| Free Cash Flow | 788K | 85.4M | 22.8M | 159M | 234M | -185M | -224M | 417M | 428M | 309M | 325M |
| Ratios | |||||||||||
| ROE | - | 39.5% | 41.9% | 32.5% | 20.7% | 31.1% | 19.4% | 14.5% | 11.6% | 6.2% | 8.2% |
| ROA | 3.3% | 27.1% | 31.7% | 27.1% | 19.0% | 27.5% | 16.1% | 12.1% | 9.9% | 5.5% | 6.9% |
| Net Profit Margin | 7.2% | 28.4% | 27.6% | 33.7% | 39.3% | 64.2% | 41.3% | 32.3% | 27.8% | 18.9% | 25.7% |
| Debt to Equity | - | 0.04x | 0.05x | 0.02x | 0.00x | 0.00x | 0.04x | 0.05x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chengdu Kanghua Biological Products dividends
- Dividend yield
- 2.10%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 62.0%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 136M | 1.05 | 62.0% |
| 2024 | CNY 268M | 2.03 | 67.2% |
| 2023 | CNY 71.6M | 0.54 | 14.1% |
| 2022 | CNY 134M | 1.00 | 22.4% |
| 2021 | CNY 90.0M | 0.67 | 10.9% |
| 2020 | CNY 231K | 0.00 | 0.1% |
| 2019 | CNY 533K | 0.00 | 0.3% |
| 2018 | CNY 5.94M | 0.06 | 3.9% |
| 2017 | CNY 21.3M | 0.16 | 28.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 25, 2022.
Who owns Chengdu Kanghua Biological Products
- Insiders 33.51%
- Institutions 8.35%
- Public & others 58.13%
- Shares outstanding 130M
- Free float 86.3M
Chengdu Kanghua Biological Products company profile
- Company name
- Chengdu Kanghua Biological Products
- Ticker
- 300841.SHE
- ISIN
- CNE100003Y57
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 550
- Fiscal year end
- December
- Address
- No. 182, Beijing Road, Chengdu, China, 610100
- Phone
- 86 28 8484 6555
- Website
- kangh.com
About Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, and operation of biological products in China. It offers freeze-dried human rabies vaccines; ACYW135 meningococcal polysaccharide vaccine. The company was founded in 2004 and is based in Chengdu, China.
Chengdu Kanghua Biological Products management
4- Mr. Wennian WuVP & Secretary · born 1983
- Mr. Huaigong ChenVP & Quality Manager · born 1972
- Mr. Fu WangVice President · born 1969
- Ping LiuAccounting Supervisor